This readme file was generated on 2023-12-03 by Jill M Hagey, MD MPH GENERAL INFORMATION Title of Dataset: Data from: Contraceptive Use Following Gestational Trophoblastic Disease: A Systematic Review Author/Principal Investigator Information Name: Jill M Hagey, MD MPH ORCID: 0000-0003-1062-8371 Institution: Duke University Department of Obstetrics and Gynecology Address: 2301 Erwin Road, Durham, NC, 27710 Email: jill.hagey@duke.edu Author/Associate or Co-investigator Information Name: Samantha Kaplan, PhD ORCID: 0000-0001-5340-1754 Institution: Duke University School of Medicine Library Address: 2301 Erwin Road, Durham, NC 27710 Email: samantha.kaplan@duke.edu Date of data collection: 2022-03-01, updated 2023-04-20 Geographic location of data collection: N/A Information about funding sources that supported the collection of the data: No funding was obtained for this project. SHARING/ACCESS INFORMATION Licenses/restrictions placed on the data: None Links to publications that cite or use the data: None Links to other publicly accessible locations of the data: None Links/relationships to ancillary data sets: None Was data derived from another source? If yes, list source(s): N/A Recommended citation for this dataset: Hagey, J.M., Drury, K.E., Kaplan S., Davidson, B.A., Morse, J.E. (2023). Data from: Contraceptive Use Following Gestational Trophoblastic Disease: A Systematic Review. Duke Research Data Repository. https://doi.org/10.7924/r4c82h56b DATA & FILE OVERVIEW File List: Contraception GTD Systematic Review Data.xlsx Relationship between files, if important: N/A Additional related data collected that was not included in the current data package: N/A Are there multiple versions of the dataset? No METHODOLOGICAL INFORMATION Description of methods used for collection/generation of data: A medical librarian with expertise in systematic searching assisted in the development of an online database search using keywords and subject headings representing the concepts of contraception and gestational trophoblastic disease. The search was peer reviewed by another medical librarian according to a modified PRESS checklist on February 25, 2022. The databases MEDLINE via PubMed, Embase via Elsevier, Scopus via Elsevier, and register ClinicalTrials.gov were searched from inception to March 1, 2022. The search was updated on April 20, 2023, resulting in the inclusion of four additional manuscripts (three case reports and one cohort study). Randomized controlled trials, observational studies and case reports were eligible for inclusion. All languages were included in the study search to reduce the risk of bias. All results were compiled in EndNote and imported into Covidence for deduplication and screening. Studies were identified in the database search as above. Manuscripts were included if they met the following PECO criteria: Population: Adolescents and adults with diagnosis of gestational trophoblastic disease Exposure: Hormonal or non-hormonal contraceptive methods used for pregnancy prevention following treatment of gestational trophoblastic disease Comparison: Other contraceptive method or no contraceptive method (not indicated for case reports) Outcomes: Time to beta-hCG remission, risk of post-molar GTN, risk of unintended pregnancy during surveillance, interactions between contraceptive methods and disease treatment Title and abstract screening was performed by two separate study authors, with discrepancies reviewed by a subset of the author group. Following title and abstract screening, full text articles were obtained. Full text screening was also performed by two separate authors, with discrepancies reviewed by a subset of the author group. Full text articles that were eligible for inclusion based on criteria above were collated for data extraction. Methods for processing the data: Data was extracted using a review-specific data extraction tool on Covidence. Study details extracted included study type, study location, study date, number and demographics of participants (including type of GTD) and aim of study. Data on the exposure of interest included number of participants using different contraceptive methods and the amount of time patients were followed on that contraceptive method. Data was also extracted on each of the outcomes including timing to beta-hCG normalization, risk of post-molar GTN, pregnancy rates or contraceptive efficacy, and interactions between contraceptive methods and disease treatment. These outcomes were extracted by contraceptive type if that data was available. Instrument- or software-specific information needed to interpret the data: N/A Standards and calibration information, if appropriate: N/A Environmental/experimental conditions: N/A Describe any quality-assurance procedures performed on the data: A quality assessment checklist for case series studies was used from the Institute of Health Economics for case reports, cohort studies and case control studies. The Cochrane Collaboration Risk of Bias Tool was used to assess quality for randomized controlled trials. People involved with sample collection, processing, analysis and/or submission: Hagey, J.M., Drury, K.E., Kaplan S., Davidson, B.A., Morse, J.E. DATA-SPECIFIC INFORMATION FOR: Contraception GTD Systematic Review Data.xlsx Number of variables: 146 Number of cases/rows: 42 Variable List: Study ID Title Lead author contact details Country in which the study was collected Aim of study Study design Start date End date Study funding sources Possible conflicts of interest for study authors Population description Inclusion criteria Exclusion criteria Method of recruitment of participants Total number of participants Type of Mole Time of Contraception Start Contraception Type: Contraception Type 1 Contraception Type: Contraception Type 2 Contraception Type: Total Population Contraception Type: Additional Notes Age (mean): Contraception Type 1 Age (mean): Contraception Type 2 Age (mean): Total Population Age (mean): Additional Notes Gravidity (mean): Contraception Type 1 Gravidity (mean): Contraception Type 2 Gravidity (mean): Total Population Gravidity (mean): Additional Notes Parity (mean): Contraception Type 1 Parity (mean): Contraception Type 2 Parity (mean): Total Population Parity (mean): Additional Notes Number of Participants on Method: Combined oral contraceptive pills Number of Participants on Method: Vaginal Ring Number of Participants on Method: Patch Number of Participants on Method: Progestin only pills Number of Participants on Method: Copper IUD Number of Participants on Method: Progestin IUD Number of Participants on Method: DMPA Number of Participants on Method: Implant Number of Participants on Method: Barrier Methods Number of Participants on Method: Other Length of Time on Method (Average): Combined oral contraceptive pills Length of Time on Method (Average): Vaginal Ring Length of Time on Method (Average): Patch Length of Time on Method (Average): Progestin only pills Length of Time on Method (Average): Copper IUD Length of Time on Method (Average): Progestin IUD Length of Time on Method (Average): DMPA Length of Time on Method (Average): Implant Length of Time on Method (Average): Barrier Methods Length of Time on Method (Average): Other Combined oral contraceptive pills: Beta-hCG Normalization Mean Time (in days) Combined oral contraceptive pills: SD Vaginal Ring: Beta-hCG Normalization Mean Time (in days) Vaginal Ring: SD Time (in days) Patch: Beta-hCG Normalization Mean Time (in days) Patch: SD Time (in days) Progestin only pills: Beta-hCG Normalization Mean Time (in days) Progestin only pills: SD Time (in days) Copper IUD: Beta-hCG Normalization Mean Time (in days) Copper IUD: SD Time (in days) Progestin IUD: Beta-hCG Normalization Mean Time (in days) Progestin IUD: SD Time (in days) DMPA: Beta-hCG Normalization Mean Time (in days) DMPA: SD Time (in days) Implant: Beta-hCG Normalization Mean Time (in days) Implant: SD Time (in days) Barrier Methods: Beta-hCG Normalization Mean Time (in days) Barrier Methods: SD Time (in days) Other: Beta-hCG Normalization Mean Time (in days) Other: SD Time (in days) None: Beta-hCG Normalization Mean Time (in days) None: SD Time (in days) Combined oral contraceptive pills: Post-Molar GTN Number of Participants Vaginal Ring: Post-Molar GTN Number of Participants Patch: Post-Molar GTN Number of Participants Progestin only pills: Post-Molar GTN Number of Participants Copper IUD: Post-Molar GTN Number of Participants Progestin IUD: Post-Molar GTN Number of Participants DMPA: Post-Molar GTN Number of Participants Implant: Post-Molar GTN Number of Participants Barrier Methods: Post-Molar GTN Number of Participants Other: Post-Molar GTN Number of Participants None: Post-Molar GTN Number of Participants Combined oral contraceptive pills: Incident Pregnancies Number of Participants Vaginal Ring: Incident Pregnancies Number of Participants Patch: Incident Pregnancies Number of Participants Progestin only pills: Incident Pregnancies Number of Participants Copper IUD: Incident Pregnancies Number of Participants Progestin IUD: Incident Pregnancies Number of Participants DMPA: Incident Pregnancies Number of Participants Implant: Incident Pregnancies Number of Participants Barrier Methods: Incident Pregnancies Number of Participants Other: Incident Pregnancies Number of Participants None: Incident Pregnancies Number of Participants Combined oral contraceptive pills: Adverse Event Combined oral contraceptive pills: Adverse Events Number of Participants Vaginal Ring: Adverse Event Vaginal Ring: Adverse Events Number of Participants Patch: Adverse Event Patch: Adverse Events Number of Participants Progestin only pills: Adverse Event Progestin only pills: Adverse Events Number of Participants Copper IUD: Adverse Event Copper IUD: Adverse Events Number of Participants Progestin IUD: Adverse Event Progestin IUD: Adverse Events Number of Participants DMPA: Adverse Event DMPA: Adverse Events Number of Participants Implant: Adverse Event Implant: Adverse Events Number of Participants Barrier Methods: Adverse Event Barrier Methods: Adverse Events Number of Participants Other: Adverse Event Other: Adverse Events Number of Participants None: Adverse Event None: Adverse Events Number of Participants RCT: Sequence generation RCT: Allocation concealment RCT: Blinding of participants and personnel RCT: Blinding of outcome assessment RCT: Incomplete outcome data RCT: Selective reporting RCT: Other sources of bias Non-RCT: Was the hypothesis/aim/objective of the study clearly stated? Non-RCT: Was the study conducted prospectively? Non-RCT: Were the cases collected in more than one center? Non-RCT: Were patients recruited consecutively? Non-RCT: Were the characteristics of the patients included in the study described? Non-RCT: Were the eligibility criteria (i.e. inclusion and exclusion criteria) for entry into the study clearly stated? Non-RCT: Did patients enter the study at a similar point in the disease? Non-RCT: Was the intervention of interest clearly described? Non-RCT: Were additional interventions (co-interventions) clearly described? Non-RCT: Were relevant outcome measures established a priori? Non-RCT: Were outcome assessors blinded to the intervention that patients received? Non-RCT: Were relevant outcomes measured using appropriate objective/subjective methods? Non-RCT: Were the relevant outcome measures made before and after the intervention? Non-RCT: Were the statistical tests used to assess the relevant outcomes appropriate? Non-RCT: Was follow-up long enough for important events and outcomes to occur? Non-RCT: Were losses to follow-up reported? Non-RCT: Did the study provide estimates of random variability in the data analysis of relevant outcomes? Non-RCT: Were the adverse events reported? Non-RCT: Were the conclusions of the study supported by results? Non-RCT: Were both competing interests and sources of support for the study reported? Missing data codes: Missing data appears as blank cells. Missing data is present when manuscripts did not report on participants using the specified contraceptive type or manuscripts did not report the specified outcome measures. Additionally, quality assessment data was divided into RCT studies (2 studies) and non-RCT studies (40 studies). Specialized formats or other abbreviations used: ActD: actinomycin D CM: complete mole COCs: combined oral contraceptives Cu IUD: copper intrauterine device DMPA: depot medroxyprogesterone acetate EE: ethinyl estradiol FA: folinic acid GTD: gestational trophoblastic disease GTN: gestational trophoblastic neoplasia GTT: gestational trophoblastic tumor HC: hormonal contraceptio IUD: intrauterine device LNG IUD: levonorgestrel intrauterine device/progestin intrauterine device L/s: laparoscopy MAC: methotrexate, actinomycin D, cyclophosphamide MOC: method of contraception MTX: methotrexate OCPs: oral contraceptive pills P: progesterone PM: partial mole SD: standard deviation